Noha. A. Saleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noha. A. Saleh has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Medhat Ibrahim
Spectroscopy Department, National Research Centre, Giza, Egypt
12 shared publications - Wael M. Elshemey
Physics Department, Faculty of Science, Islamic University of Madinah, Madinah, Kingdom of Saudi Arabia
7 shared publications Anwar A. Elsayed
4 shared publications- Abdo A. Elfiky
Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt
3 shared publications Ahmed A. Ezat
Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt
3 shared publications- Hanan Elhaes
Physics Department, Faculty of Women for Arts, Science and Education, Ain Shams University, Cairo, Egypt
3 shared publications
Latest Publications
- 21 March 2019
- Published by Springer Nature in VirusDisease
- Vol. 30 (2) , 207-213
Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study
In 2011, the FDA approved boceprevir as a hepatitis C virus (HCV) NS3 serine protease inhibitor. The sustained virological response rate for treatment with this approved compound is considerably low. Patients have not responded as much as expected to boceprevir therapy. In this in silico study, modified boceprevir compounds are suggested and tested on wild-type HCV NS3 protease and 19 mutated HCV NS3 proteases using molecular docking. Results reveal the superiority of two of the proposed modified compounds to boceprevir. One of which appears to be more potent than boceprevir itself concerning activity against wild-type NS3 and most of the examined mutated NS3 proteases.
- 21 March 2019
- Published by Springer Nature in VirusDisease
- Vol. 30 (2) , 207-213
Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study
In 2011, the FDA approved boceprevir as a hepatitis C virus (HCV) NS3 serine protease inhibitor. The sustained virological response rate for treatment with this approved compound is considerably low. Patients have not responded as much as expected to boceprevir therapy. In this in silico study, modified boceprevir compounds are suggested and tested on wild-type HCV NS3 protease and 19 mutated HCV NS3 proteases using molecular docking. Results reveal the superiority of two of the proposed modified compounds to boceprevir. One of which appears to be more potent than boceprevir itself concerning activity against wild-type NS3 and most of the examined mutated NS3 proteases.
- 13 January 2019
- Published by Egyptian Knowledge Bank in Egyptian Journal of Physics
The calculated binding energy of peptide-mimic inhibitors with some mutated HCV NS3 protease
Hepatitis C virus is considered one of the worldwide viruses with very large percentage of infection in population. It is as an epidemic disease in Egypt. Previously, the introduced compounds (a and b) in this study were investigated and gave good binding affinity and good inhibition activity with wild-type HCV NS3 protease. In the present work, the calculated molecular docking and the binding energy calculations are performed to predict the inhibition activity of suggested compounds against some mutated HCV NS3 proteases. Compound a has hexa-peptide with α-ketoacids instead of the thiol group (SH) of cysteine residues attached to monomer cellulose at position 6 and compound b has hexa-peptide with α-ketoacids instead of the thiol group (SH) of cysteine residues attached to dimer cellulose at position 6. Based on the calculated binding energy and the number of hydrogen bonds in docking interaction between the compounds and mutated NS3 protease, the inhibition activity of compounds a and b with NS3 protease mutations is more than that with wild-type NS3 protease. Especially with D168V NS3 protease mutation. The mutation in virus enzymes is one of the major obstacles in hepatitis C virus treatment.
- 13 January 2019
- Published by Egyptian Knowledge Bank in Egyptian Journal of Physics
The calculated binding energy of peptide-mimic inhibitors with some mutated HCV NS3 protease
Hepatitis C virus is considered one of the worldwide viruses with very large percentage of infection in population. It is as an epidemic disease in Egypt. Previously, the introduced compounds (a and b) in this study were investigated and gave good binding affinity and good inhibition activity with wild-type HCV NS3 protease. In the present work, the calculated molecular docking and the binding energy calculations are performed to predict the inhibition activity of suggested compounds against some mutated HCV NS3 proteases. Compound a has hexa-peptide with α-ketoacids instead of the thiol group (SH) of cysteine residues attached to monomer cellulose at position 6 and compound b has hexa-peptide with α-ketoacids instead of the thiol group (SH) of cysteine residues attached to dimer cellulose at position 6. Based on the calculated binding energy and the number of hydrogen bonds in docking interaction between the compounds and mutated NS3 protease, the inhibition activity of compounds a and b with NS3 protease mutations is more than that with wild-type NS3 protease. Especially with D168V NS3 protease mutation. The mutation in virus enzymes is one of the major obstacles in hepatitis C virus treatment.
- 1 October 2017
- Published by Elsevier in Life Sciences
- Vol. 187, 58-63
Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors
- 1 October 2017
- Published by Elsevier in Life Sciences
- Vol. 187, 58-63
Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors
- 1 May 2017
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 14 (5) , 2298-2301
Molecular Modeling Analyses of Modified Polyvinylalchol/Hydroxyapatite Composite
Polyvinylalcohol (PVA)/Hydroxyapatite (HA) is forming a composite named (HAV). A model molecule for HAV composite consisting of 4 PVA units and hydroxyapatite was proposed then modified with Au, Ag and Cu, respectively. The reactivity of the studied composites was calculated with PM6 semi-empirical quantum mechanical model as well as Quantitative Structure-Activity Relationships (QSAR). Results indicate that addition of gold, silver and copper to HAV decreased its total energy and enhance its stability. The HAV is easier to interact with the surrounding systems which enable it for further interaction with gold, silver and copper. The molar refractivity is increased with adding metal ions for HAV with an increase in surface properties and reactivity of the studied composite.
- 1 May 2017
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 14 (5) , 2298-2301
Molecular Modeling Analyses of Modified Polyvinylalchol/Hydroxyapatite Composite
Polyvinylalcohol (PVA)/Hydroxyapatite (HA) is forming a composite named (HAV). A model molecule for HAV composite consisting of 4 PVA units and hydroxyapatite was proposed then modified with Au, Ag and Cu, respectively. The reactivity of the studied composites was calculated with PM6 semi-empirical quantum mechanical model as well as Quantitative Structure-Activity Relationships (QSAR). Results indicate that addition of gold, silver and copper to HAV decreased its total energy and enhance its stability. The HAV is easier to interact with the surrounding systems which enable it for further interaction with gold, silver and copper. The molar refractivity is increased with adding metal ions for HAV with an increase in surface properties and reactivity of the studied composite.
- 1 January 2017
- Published by Elsevier
- p. 25-58
Design and Development of Some Viral Protease Inhibitors by QSAR and Molecular Modeling Studies
- 1 January 2017
- Published by Elsevier
- p. 25-58
Design and Development of Some Viral Protease Inhibitors by QSAR and Molecular Modeling Studies
- 1 March 2015
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 12 (3) , 371-375
Theoretical Study on Modified Boceprevir Compounds as NS3 Protease Inhibitors
- 1 March 2015
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 12 (3) , 371-375
Theoretical Study on Modified Boceprevir Compounds as NS3 Protease Inhibitors
- 1 February 2015
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 136, 1523-1529
The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors
- 1 February 2015
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 136, 1523-1529
The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors
- 1 October 2014
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 11 (10) , 2136-2140
Molecular Spectroscopic Study of Fulleropyrrolidine Carbodithioic Acid
- 1 October 2014
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 11 (10) , 2136-2140
Molecular Spectroscopic Study of Fulleropyrrolidine Carbodithioic Acid
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 10 (1) , 28-40
QSAR Analysis and Molecular Docking Simulation of Suggested Peptidomimetic NS3 Protease Inhibitors
Abstract: Based on the N-terminal hexapeptide product of hydrolysis (EDVVCC) at HCV NS5A/5B junction, three modified groups of compounds are built. The first group contains linear peptides while the second and third groups contain P1-P3 and P2-P4 macrocyclic structures, respectively. Quantitative Structure Activity Relationship (QSAR) characterization and docking simulations are performed in order to investigate the potential of these compounds as HCV NS3/4A protease inhibitors. Based on the QSAR properties, the three most stable compounds due to their lowest total energy are P1-P3 and P2-P4 macrocycles of azahexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azahexapeptide sequence (DDIVP norvaline). They also have high surface area, solvent accessible surface area, volume, molar refractivity and polarizabilty. They have moderately low dipole moment and good log P values, as well. The docking scores of the best two P2-P4 macrocycles are just acceptable. The two compounds 5A/5B hexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azapentapeptide sequence (DIVP vinyl amino cyclopropane) yielded the best docking scores.
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 10 (1) , 28-40
QSAR Analysis and Molecular Docking Simulation of Suggested Peptidomimetic NS3 Protease Inhibitors
Abstract: Based on the N-terminal hexapeptide product of hydrolysis (EDVVCC) at HCV NS5A/5B junction, three modified groups of compounds are built. The first group contains linear peptides while the second and third groups contain P1-P3 and P2-P4 macrocyclic structures, respectively. Quantitative Structure Activity Relationship (QSAR) characterization and docking simulations are performed in order to investigate the potential of these compounds as HCV NS3/4A protease inhibitors. Based on the QSAR properties, the three most stable compounds due to their lowest total energy are P1-P3 and P2-P4 macrocycles of azahexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azahexapeptide sequence (DDIVP norvaline). They also have high surface area, solvent accessible surface area, volume, molar refractivity and polarizabilty. They have moderately low dipole moment and good log P values, as well. The docking scores of the best two P2-P4 macrocycles are just acceptable. The two compounds 5A/5B hexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azapentapeptide sequence (DIVP vinyl amino cyclopropane) yielded the best docking scores.